Prostaglandin E1(PGE1): Side effects after administration in neonates with severe congenital cardiac defects

UENPS.389 Prostaglandin E1(PGE1): Side effects after administration in neonates with severe congenital cardiac defects Manuela Cucerea⁎, Marta Simon, Monika Rusneac, Luminita Zahiu, Delia Tatar, Corina Rac, Madalina Cioata University of Medicine and Pharmacy, Tirgu Mures, Romania Emergency Clinic County Hospital, Tirgu Mures, Romania Background and aim PGE1 is routinely used in neonates with ductus-dependent congenital heart disease to improve circulation prior septostomy or corrective surgery. It is an effective drug for keeping the ductus arteriosus open or for restoring ductal patency if administered soon after ductal closure. The PGE1 therapy may produce several adverse effects. Objectives: to assess the side effects of PGE1 administration in our center. Materials and methods 17 neonates treated with PGE1 (Prostin) in Mures regional NICU Romania, were included in a retrospective study since 1 July 2007 to 1 July 2008. Prostin was started in an initial dose of 0.05–0.1 μg/kg/min, decreased to 0.005–0.01 μg/kg/min for maintenance.